Pediatric Hematology-Oncology; Pediatrics
I joined the faculty of the Jacobs School of Medicine and Biomedical Sciences in 2016 as Professor of Oncology and Director of Pediatric Developmental Therapeutics at the Roswell Park Comprehensive Cancer Center. I am a board-certified pediatric hematologist/oncologist and clinical investigator. My area of clinical expertise focuses on solid tumor malignancies in children and young adults. My research interests have been driven by the clinical challenges in high risk pediatric malignancies. A major focus of my clinical investigation effort over the past 15 years has been in the design of clinical trials through the Children’s Oncology Group (COG) for patients with neuroblastoma. I have served since 2006 on the COG Neuroblastoma Steering Committee, helping to define and prioritize research objectives for this disease. I served as study chair of the COG Phase III study ANBL0531 for patients with Intermediate Risk Neuroblastoma, which defined a practice-changing new standard of care therapy for patients with non-high risk neuroblastoma in North America.
Since joining the faculty in the Cancer and Blood Disorders Program at Roswell Park and Oishei Children’s Hospital in 2016, I have overseen the clinical trials program for pediatric oncology and serve as the institutional principal investigator for COG. In my role as Director of Pediatric Developmental Therapeutics at Roswell Park, I am building a program to support the development and implementation of early phase trials and novel therapies for children and young adults with high risk malignancies.
I serve as the Program Director of the Pediatric Hematology/Oncology Fellowship Training Program at the Jacobs School and Roswell Park/Oishei Children’s Hospital. On a national level, I have served on the Education Committee of the American Society of Clinical Oncology (ASCO), the Training Committee and the Certification and Continuing Education Committee of the American Society of Pediatric Hematology/Oncology (ASPHO) and the National Heart, Lung, and Blood Institute (NHLBI) Taskforce on the Future of the Workforce in Hematology, as well as serving on the American Board of Pediatrics subboard in Hematology/Oncology since 2008.